MoneyWorks4Me

CRISIL upgrades ratings of Bafna Pharmaceuticals’ bank facilities

19 Nov 2014 Evaluate

Credit rating agency, CRISIL has upgraded rating of Bafna Pharmaceuticals’ long term bank facilities to ‘BB-’ from ‘D’. The rating agency has also upgraded rating of the company’s short term bank facilities to ‘A4+’ from ‘D’.

Bafna Pharmaceutical is a Chennai-based Pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum. The company has 173 products registered in UK, Sri Lanka, Nepal, Ukraine, Ghana, Ethiopia, Philippines, Kryghistan, Georgia, Honduras, Colombia, Uzbekhistan, Vietnam and Nigeria.

Bafna Pharmaceutical Share Price

262.40 -5.35 (-2.00%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: